Kayvan Moussavi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kayvan Moussavi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Scott Fitter
Clinical Pharmacy - Emergency Medicine, Loma Linda University Medical Center, Loma Linda, California; Loma Linda University School of Pharmacy, Loma Linda, California
3 shared publications- Elizabeth Nam
Clinical Pharmacist, Loma Linda University Medicial Center, Loma Linda, CA, USA
2 shared publications Henry Hua
Department of Pharmacy Practice, College of Pharmacy, Marshall B. Ketchum University, Fullerton, California
2 shared publications- Aaron G. Matlock
Department of Emergency Medicine, Brooke Army Medical Center, Fort Sam Houston, USA
1 shared publication Ashley Tuttle
Clinical Pharmacist, Loma Linda University Medical Center, Loma Linda, California
1 shared publication- Brit Long
Department of Emergency Medicine, Mayo Clinic College of Medicine, Rochester, MN
1 shared publication
Latest Publications
- Open Access
- 7 November 2022
- Published by Elsevier in American Journal of Medicine Open
- Vol. 8
Corticosteroid administration and glycemic outcomes during treatment of acute exacerbation of chronic obstructive pulmonary disease
- 7 November 2022
- Published by Elsevier in American Journal of Medicine Open
- Vol. 8
Open AccessCorticosteroid administration and glycemic outcomes during treatment of acute exacerbation of chronic obstructive pulmonary disease
- 11 October 2022
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 63 (3) , 399-413
The Effects of Magnesium Coadminstration During Treatment of Hypokalemia in the Emergency Department
- 11 October 2022
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 63 (3) , 399-413
The Effects of Magnesium Coadminstration During Treatment of Hypokalemia in the Emergency Department
- 11 March 2022
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 58, 325-326
The authors respond: Use of Push-Dose Vasopressors in the Emergency Department
- 11 March 2022
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 58, 325-326
The authors respond: Use of Push-Dose Vasopressors in the Emergency Department
- 1 February 2022
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 52, 43-49
Comparison of push-dose phenylephrine and epinephrine in the emergency department
- 1 February 2022
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 52, 43-49
Comparison of push-dose phenylephrine and epinephrine in the emergency department
- 1 August 2021
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 13 (8) , 914-921
Burnout assessment at a college of pharmacy, college of optometry, and school of physician assistant studies
- 1 August 2021
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 13 (8) , 914-921
Burnout assessment at a college of pharmacy, college of optometry, and school of physician assistant studies
- 16 May 2021
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 41 (7) , 598-607
Reduced alternative insulin dosing in hyperkalemia: A meta‐analysis of effects on hypoglycemia and potassium reduction
Study Objective: Recent studies have identified that reduced alternative intravenous insulin doses, such as 5 units or 0.1 units/kg, may reduce the risk of hypoglycemia compared to standard doses of 10 units in patients treated for hyperkalemia. However, some studies suggest that these alternative doses may reduce the ability to lower serum potassium. This study was performed to determine the impact of alternative insulin dosing on hypoglycemia and potassium reduction in patients with hyperkalemia.Design: Meta‐analysis.Data Source: PubMed/MEDLINE, CENTRAL, Ovid, and ClinicalTrials.gov were searched from inception through November 2020.Patients: Patients treated with standard (10 units) or alternative (n = 3437) were included and had low‐ or moderate‐risk of bias. Alternative insulin dosing strategies included 5 units, 0.1 units/kg, and I2 = 8%) and severe hypoglycemia (OR 0.41, 95% CI 0.27–0.64, I2 = 0%). No difference in potassium reduction was detected (mean difference −0.02 mmol/L, 95% CI −0.11–0.07, I2 = 53%).Conclusions: Alternative insulin dosing strategies for hyperkalemia management resulted in less hypoglycemia and severe hypoglycemia without compromising potassium reduction compared to standard dose. Prospective studies are needed to confirm these findings.
- 16 May 2021
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 41 (7) , 598-607
Reduced alternative insulin dosing in hyperkalemia: A meta‐analysis of effects on hypoglycemia and potassium reduction
Study Objective: Recent studies have identified that reduced alternative intravenous insulin doses, such as 5 units or 0.1 units/kg, may reduce the risk of hypoglycemia compared to standard doses of 10 units in patients treated for hyperkalemia. However, some studies suggest that these alternative doses may reduce the ability to lower serum potassium. This study was performed to determine the impact of alternative insulin dosing on hypoglycemia and potassium reduction in patients with hyperkalemia.Design: Meta‐analysis.Data Source: PubMed/MEDLINE, CENTRAL, Ovid, and ClinicalTrials.gov were searched from inception through November 2020.Patients: Patients treated with standard (10 units) or alternative (n = 3437) were included and had low‐ or moderate‐risk of bias. Alternative insulin dosing strategies included 5 units, 0.1 units/kg, and I2 = 8%) and severe hypoglycemia (OR 0.41, 95% CI 0.27–0.64, I2 = 0%). No difference in potassium reduction was detected (mean difference −0.02 mmol/L, 95% CI −0.11–0.07, I2 = 53%).Conclusions: Alternative insulin dosing strategies for hyperkalemia management resulted in less hypoglycemia and severe hypoglycemia without compromising potassium reduction compared to standard dose. Prospective studies are needed to confirm these findings.
- 6 May 2021
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 16 (8) , 2231-2241
Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections
Antimicrobial resistance is a growing threat to public health and an increasingly common problem for acute care physicians to confront. Several novel antibiotics have been approved in the past decade to combat these infections; however, physicians may be unfamiliar with how to appropriately utilize them. The purpose of this review is to evaluate novel antibiotics active against resistant gram-negative bacteria and highlight clinical information regarding their use in the acute care setting. This review focuses on novel antibiotics useful in the treatment of infections caused by resistant gram-negative organisms that may be seen in the acute care setting. These novel antibiotics include ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilistatin/relebactam, cefiderocol, plazomicin, eravacycline, and omadacycline. Acute care physicians should be familiar with these novel antibiotics so they can utilize them appropriately.
- 6 May 2021
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 16 (8) , 2231-2241
Advances in novel antibiotics to treat multidrug-resistant gram-negative bacterial infections
Antimicrobial resistance is a growing threat to public health and an increasingly common problem for acute care physicians to confront. Several novel antibiotics have been approved in the past decade to combat these infections; however, physicians may be unfamiliar with how to appropriately utilize them. The purpose of this review is to evaluate novel antibiotics active against resistant gram-negative bacteria and highlight clinical information regarding their use in the acute care setting. This review focuses on novel antibiotics useful in the treatment of infections caused by resistant gram-negative organisms that may be seen in the acute care setting. These novel antibiotics include ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilistatin/relebactam, cefiderocol, plazomicin, eravacycline, and omadacycline. Acute care physicians should be familiar with these novel antibiotics so they can utilize them appropriately.
- Open Access
- 1 April 2020
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 2 (4) , e0092
Comparison of IV Insulin Dosing Strategies for Hyperkalemia in the Emergency Department
Objectives: The objectives of this study were to evaluate the safety and efficacy of insulin dosing of less than 10 units versus 10 units in patients receiving hyperkalemia treatment. Design: Retrospective single-center study. Setting: Emergency department at a large academic medical center in the United States. Patients: Seven hundred adults treated for hyperkalemia with IV regular insulin between April 1, 2013, and September 27, 2018. Interventions: Patients that received less than 10 units of insulin were compared to those that received 10 units of insulin. Measurements and Main Results: Patients treated with less than 10 units had significantly lower frequency of hypoglycemia (11.2% vs 17.6%; p = 0.008). Reduction in serum potassium was significantly more modest in size in patients treated with less than 10 units (mean reduction 0.94 ± 0.71 mMol/L) compared with patients treated with 10 units (mean reduction 1.11 ± 0.8 mMol/L; p = 0.008). There were no statistically significant differences between groups in time to hypoglycemia, nadir serum glucose, severe hypoglycemia (<40 mg/dL), dextrose requirements, use of concurrent agents for hyperkalemia, need for repeat insulin dosing, length of stay, or mortality. Conclusions: Patients treated for hyperkalemia with insulin doses less than 10 units had reduced frequency of hypoglycemia; however, potassium reduction post treatment was more modest in these patients. These findings suggest providers choosing to administer 10 units IV insulin should ensure patients have adequate monitoring for hypoglycemia.
- 1 April 2020
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 2 (4) , e0092
Open AccessComparison of IV Insulin Dosing Strategies for Hyperkalemia in the Emergency Department
Objectives: The objectives of this study were to evaluate the safety and efficacy of insulin dosing of less than 10 units versus 10 units in patients receiving hyperkalemia treatment. Design: Retrospective single-center study. Setting: Emergency department at a large academic medical center in the United States. Patients: Seven hundred adults treated for hyperkalemia with IV regular insulin between April 1, 2013, and September 27, 2018. Interventions: Patients that received less than 10 units of insulin were compared to those that received 10 units of insulin. Measurements and Main Results: Patients treated with less than 10 units had significantly lower frequency of hypoglycemia (11.2% vs 17.6%; p = 0.008). Reduction in serum potassium was significantly more modest in size in patients treated with less than 10 units (mean reduction 0.94 ± 0.71 mMol/L) compared with patients treated with 10 units (mean reduction 1.11 ± 0.8 mMol/L; p = 0.008). There were no statistically significant differences between groups in time to hypoglycemia, nadir serum glucose, severe hypoglycemia (<40 mg/dL), dextrose requirements, use of concurrent agents for hyperkalemia, need for repeat insulin dosing, length of stay, or mortality. Conclusions: Patients treated for hyperkalemia with insulin doses less than 10 units had reduced frequency of hypoglycemia; however, potassium reduction post treatment was more modest in these patients. These findings suggest providers choosing to administer 10 units IV insulin should ensure patients have adequate monitoring for hypoglycemia.
- 19 June 2019
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 34 (1) , 17-22
Evaluation of the Two-Bag System in Adult Diabetic Ketoacidosis Patients
Diabetic ketoacidosis (DKA) is a serious complication of diabetes mellitus (DM). This study was designed to assess if the two-bag (TB) system, which utilizes 2 intravenous (IV) fluid bags, one containing sodium chloride and the other containing sodium chloride and dextrose, is an effective and safe alternative to the traditional one-bag (OB) system in adults with DKA. A retrospective review was performed at an academic medical center. Adults with DKA were included if treated with the OB or TB system. The primary outcome was time to anion gap closure. Secondary outcomes included duration of insulin infusion, time to serum bicarbonate correction, number of continuous IV fluid orders, intensive care unit (ICU) and hospital length of stay (LOS), and rates of hypoglycemia and hypokalemia. One hundred twenty-two patients were included. Sixty-eight were treated with the OB system and 54 with the TB system. There were no differences in time to anion gap closure, duration of insulin infusion, ICU LOS, or hospital LOS. Time to bicarbonate correction was shorter in the OB group (13.5 [IQR: 7-29] vs 25 [IQR: 11-50] hours; P = .03). There were no differences in rates of hypoglycemia or hypokalemia between groups. The TB system had similar efficacy and safety when compared to the OB system. Both approaches can be considered in adults with DKA.
- 19 June 2019
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 34 (1) , 17-22
Evaluation of the Two-Bag System in Adult Diabetic Ketoacidosis Patients
Diabetic ketoacidosis (DKA) is a serious complication of diabetes mellitus (DM). This study was designed to assess if the two-bag (TB) system, which utilizes 2 intravenous (IV) fluid bags, one containing sodium chloride and the other containing sodium chloride and dextrose, is an effective and safe alternative to the traditional one-bag (OB) system in adults with DKA. A retrospective review was performed at an academic medical center. Adults with DKA were included if treated with the OB or TB system. The primary outcome was time to anion gap closure. Secondary outcomes included duration of insulin infusion, time to serum bicarbonate correction, number of continuous IV fluid orders, intensive care unit (ICU) and hospital length of stay (LOS), and rates of hypoglycemia and hypokalemia. One hundred twenty-two patients were included. Sixty-eight were treated with the OB system and 54 with the TB system. There were no differences in time to anion gap closure, duration of insulin infusion, ICU LOS, or hospital LOS. Time to bicarbonate correction was shorter in the OB group (13.5 [IQR: 7-29] vs 25 [IQR: 11-50] hours; P = .03). There were no differences in rates of hypoglycemia or hypokalemia between groups. The TB system had similar efficacy and safety when compared to the OB system. Both approaches can be considered in adults with DKA.
- Open Access
- 9 April 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (4) , 478
Vitamin C, Hydrocortisone, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Analysis of Real-World Application
A recent study suggested mortality benefits using vitamin C, hydrocortisone, and thiamine combination therapy (triple therapy) in addition to standard care in patients with severe sepsis and septic shock. In order to further evaluate the effects of triple therapy in real-world clinical practice, we conducted a retrospective observational cohort study at an academic tertiary care hospital. A total of 94 patients (47 in triple therapy group and 47 in standard care group) were included in the analysis. Baseline characteristics in both groups were well-matched. No significant difference in the primary outcome, hospital mortality, was seen between triple therapy and standard care groups (40.4% vs. 40.4%; p = 1.000). In addition, there were no significant differences in secondary outcomes, including intensive care unit (ICU) mortality, requirement for renal replacement therapy for acute kidney injury, ICU length of stay, hospital length of stay, and time to vasopressor independence. When compared to standard care, triple therapy did not improve hospital or ICU mortality in patients with septic shock. A randomized controlled trial evaluating the effects of triple therapy is necessary prior to implementing vitamin C, hydrocortisone, and thiamine combination therapy as a standard of care in patients with septic shock.
- 9 April 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (4) , 478
Open AccessVitamin C, Hydrocortisone, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Analysis of Real-World Application
A recent study suggested mortality benefits using vitamin C, hydrocortisone, and thiamine combination therapy (triple therapy) in addition to standard care in patients with severe sepsis and septic shock. In order to further evaluate the effects of triple therapy in real-world clinical practice, we conducted a retrospective observational cohort study at an academic tertiary care hospital. A total of 94 patients (47 in triple therapy group and 47 in standard care group) were included in the analysis. Baseline characteristics in both groups were well-matched. No significant difference in the primary outcome, hospital mortality, was seen between triple therapy and standard care groups (40.4% vs. 40.4%; p = 1.000). In addition, there were no significant differences in secondary outcomes, including intensive care unit (ICU) mortality, requirement for renal replacement therapy for acute kidney injury, ICU length of stay, hospital length of stay, and time to vasopressor independence. When compared to standard care, triple therapy did not improve hospital or ICU mortality in patients with septic shock. A randomized controlled trial evaluating the effects of triple therapy is necessary prior to implementing vitamin C, hydrocortisone, and thiamine combination therapy as a standard of care in patients with septic shock.